National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Icatibant (Firazyr®) indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (type I and II HAE).

Rapid Review

Commenced Completed Outcome
22 July 2013 31 July 2013 Full pharmacoeconomic evaluation not recommended